VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2023 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Mark Flather – Vice President-Investor Relations Shawn Singh – Chief Executive Officer Jerry Dotson – Chief Financial Officer Conference Call Participants Brian Skorney – Baird Operator Welcome to the VistaGen Therapeutics First Quarter Fiscal Year 2023 Results Conference Call. [Operator Instructions] I’ll now turn the call over to your host, Mark Flather, Vice President of Investor Rel ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2022 Earnings Conference Call June 23, 2022 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Vice President, Chief Financial Officer and Secretary Mark Smith - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies LLC Lachlan Hanbury-Brown - William Blair & Company, LLC Luke Herrmann - Robert W. Baird & Co. Michael Okunewitch - Maxim Group LLC Operator G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Nevada 20-5093315 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) For the fiscal year ended: March 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commis ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2022 Earnings Conference Call February 10, 2022 5:00 PM ET Company Participants Mark Flather - Vice President, Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Mark Smith - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Lachlan Hanbury-Brown - William Blair Luke Herrmann - Baird Joanne Lee - Maxim Group Operator Greetings and welcome to VistaGen Therapeutics’ Third Quarter of Fiscal Year 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 20-5093315 (I.R.S. Employer Identification No.) 343 Alle ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2022 Earnings Conference Call November 10, 2021 5:00 PM ET Company Participants Mark Flather – Vice President of Investor Relations Shawn Singh – Chief Executive Officer Jerry Dotson – Chief Financial Officer Mark Smith – Chief Medical Officer Conference Call Participants Brian Skorney – Robert W. Baird Tim Lugo – William Blair Jason McCarthy – Maxim Group Andrew Tsai – Jefferies Operator Greetings, and welcome to VistaGen Therapeutic Second Quarter of Fiscal Yea ...

Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2022 Earnings Conference Call August 12, 2021 5:00 PM ET Company Participants Mark Flather - Vice President, Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Mark Smith - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Operator Greetings, and welcome to the VistaGen Therapeutics First Quarter 2022 Results Conference Call. During the presentation, all participants will be in a listen-only m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Indicate by check mark whether the regi ...